Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | LTA4H | P09960 | 3/20 | 0.58 |
| ▸ | EPOR | P19235 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 3/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.52 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.50 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | PTGES | O14684 | 1/20 | 0.49 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6600006 | 0.87 | KMT2A (0.62) | KMT2ASMN1; SMN2LTA4HMAOBALOX5 | |
| SCHEMBL9432429 | 0.85 | KMT2A (0.59) | KMT2ASMN1; SMN2LTA4HEPORMAOB | |
| SCHEMBL2853880 | 0.85 | ALOX5 (0.63) | KMT2ASMN1; SMN2LTA4HEPORMAOB | |
| SCHEMBL9019941 | 0.85 | KMT2A (0.59) | KMT2ASMN1; SMN2LTA4HEPORMAOB | |
| SCHEMBL3619364 | 0.85 | LTA4H (0.64) | SMN1; SMN2LTA4HEPORMAOBALOX5 | |
| SCHEMBL25311665 | 0.84 | KMT2A (0.57) | KMT2ASMN1; SMN2LTA4HEPORMAOB | |
| SCHEMBL31070956 | 0.84 | KMT2A (0.57) | KMT2ASMN1; SMN2LTA4HEPORMAOB | |
| SCHEMBL19415900 | 0.84 | KMT2A (0.50) | KMT2ASMN1; SMN2LTA4HMEN1 | |
| SCHEMBL30771265 | 0.84 | SGMS2 (0.58) | KMT2ASMN1; SMN2LTA4HEPORMAOB | |
| SCHEMBL3622668 | 0.82 | PTGS1 (0.59) | KMT2AALOX5MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3303328-B1 | AMINOESTER DERIVATIVES | CHIESI FARM SPA (IT) | 2019-03-20 | — | — | EP | disclosed |
| EP-3303328-B1 | AMINOESTER DERIVATIVES | CHIESI FARM SPA (IT) | 2019-03-20 | — | — | EP | disclosed |
| EP-3303328-A1 | AMINOESTER DERIVATIVES | Chiesi Farmaceutici S.p.A. (IT) | 2018-04-11 | — | — | EP | disclosed |
| CN-107667103-A | Amino ester derivatives | 奇斯药制品公司 | 2018-02-06 | — | — | CN | disclosed |
| EP-3077385-B1 | HETEROARYL DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES | CHIESI FARM SPA (IT) | 2017-10-04 | — | — | EP | disclosed |
| EP-3077385-B1 | HETEROARYL DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES | CHIESI FARM SPA (IT) | 2017-10-04 | — | — | EP | disclosed |
| US-9636336-B2 | Aminoester derivatives | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-05-02 | — | — | US | disclosed |
| US-9636336-B2 | Aminoester derivatives | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-05-02 | — | — | US | disclosed |
| US-9636336-B2 | Aminoester derivatives | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-05-02 | — | — | US | disclosed |
| WO-2016193244-A1 | AMINOESTER DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-12-08 | — | — | WO | disclosed |
| WO-2015082616-A1 | HETEROARYL DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-06-11 | — | — | WO | disclosed |
| US-20150158858-A1 | HETEROARYL DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-06-11 | — | — | US | disclosed |
| WO-2015082616-A1 | HETEROARYL DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-06-11 | — | — | WO | disclosed |
| EP-2114906-B1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS FOR CNS DISORDERS | HOFFMANN LA ROCHE (CH) | 2014-08-06 | — | — | EP | disclosed |
| US-8604061-B2 | 2-aminooxazolines as TAAR1 ligands | HOFFMANN-LA ROCHE INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-20120196903-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | GALLEY GUIDO (DE) | 2012-08-02 | — | — | US | disclosed |
| US-20100120864-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | GALLEY GUIDO | 2010-05-13 | — | — | US | disclosed |
| EP-2114906-A1 | NOVEL 2-AMINOOXAZOLINES AS TAAR1 LIGANDS FOR CNS DISORDERS | F. Hoffmann-Roche AG (CH) | 2009-11-11 | — | — | EP | disclosed |
| US-20080261920-A1 | 2-Aminooxazolines as TAAR1 ligands | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-23 | — | — | US | disclosed |
| WO-2008092785-A1 | NOVEL 2-AMINOOXAZOLINES AS TAAR1 LIGANDS FOR CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120864-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | TAAR1, TAAR5, NPY2R | KMT2A 1861/4885SMN1; SMN2 2406/4885LTA4H 1928/4885 |
| US-20120196903-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | TAAR1, TAAR5, NPY2R | KMT2A 1828/4885SMN1; SMN2 2411/4885LTA4H 2305/4885 |
| US-20080261920-A1 | 2-Aminooxazolines as TAAR1 ligands | TAAR1, TAAR5, NPY2R | KMT2A 1861/4885SMN1; SMN2 2406/4885LTA4H 1928/4885 |
| US-20150158858-A1 | HETEROARYL DERIVATIVES | PDE4A, PDE4B, PDE3A | KMT2A 2493/4885SMN1; SMN2 4045/4885LTA4H 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.